A detailed history of Raymond James Financial Inc transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 70,584 shares of MDGL stock, worth $37.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
70,584
Previous 54,933 28.49%
Holding current value
$37.4 Million
Previous $16.6 Million 94.74%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$287.52 - $458.66 $4.5 Million - $7.18 Million
15,651 Added 28.49%
70,584 $32.4 Million
Q2 2025

Aug 14, 2025

BUY
$267.56 - $340.8 $272,108 - $346,593
1,017 Added 1.89%
54,933 $16.6 Million
Q1 2025

May 13, 2025

BUY
$272.79 - $355.88 $19,095 - $24,911
70 Added 0.13%
53,916 $17.9 Million
Q4 2024

Feb 06, 2025

BUY
$202.45 - $354.85 $10.9 Million - $19.1 Million
53,846 New
53,846 $16.6 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $9.05B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Raymond James Financial Inc Portfolio

Follow Raymond James Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Inc with notifications on news.